PRSS21 cfDNA methylation did not show significant changes in blood plasma between NSE patients and controls, likely due to the blending of highly methylated PRSS21 cfDNA levels in healthy plasma with highly methylated tumor PRSS21 cfDNA [17, 52]. The gene discussed is ENO2; the disease is neoplasm.